Effect of irinotecan,paclitaxel combined with cisplatin on levels of CYFRA21-1,VEGF-C and LC3-Ⅱ in cervical cancer
Objective:To analyze the therapeutic effect of irinotecan,paclitaxel combined with cisplatin on cervical cancer and its effect on Cytokeratin 19 fragment 21-1,CYFRA21-1),Vascular endothelial growth factor C(Vascular endothelial growth factor C,Effects of VEGF-C and Microtubule-associated protein 1 light chain 3(LC3-Ⅱ)levels.Methods:The clinical data of 122 patients with cervical cancer admitted to our hospital from March 2020 to April 2023 were retrospectively analyzed,and the patients were divided into IP group(irinotecan + cisplatin treatment,60 cases)and TP group(paclitaxel + cisplatin treatment,62 cases)according to different treatment regimen.The clinical efficacy,levels of CYFRA21-1,VEGF-C,LC3-Ⅱ and toxicity of the two groups were analyzed and compared.Results:The total curative effect rate of IP group and TP group was 56.67%and 79.03%,respectively.The total curative effect rate of TP group was significantly higher than that of IP group(P<0.05).After treatment,the levels of CYFRA21-1,VEGF-C and LC3-Ⅱ in both groups were significantly decreased,and the levels of CYFRA21-1,VEGF-C and LC3-Ⅱ in TP group were significantly lower than those in IP group(P<0.05).The proportion of 0 degree and Ⅰ degree cases in TP group was significantly higher than that in IP group,and the proportion of Ⅲ degree cases was significantly lower than that in IP group(P<0.05).Conclusion:Compared with irinotec combined with cisplatin,paclitaxel combined with cisplatin has better clinical efficacy in the treatment of cervical cancer,and can effectively reduce the levels of CYFRA21-1,VEGF-C and LC3-Ⅱ,with high safety.
NETL
NSTL
万方数据
